比美单抗治疗化脓性扁桃体炎的实际有效性和安全性:一项前瞻性观察研究。

IF 2.2 4区 医学 Q2 DERMATOLOGY
Miguel Mansilla-Polo MD, Martí Pons-Benavent MD, Pablo Fernández-Crehuet MD, PhD, Eva Vilarrasa MD, PhD, Cristina Albanell-Fernández MD, Enrico Morales-Tedone MD, Francisca Rausell-Félix MD, Rebeca Alcalá-García, María Matellanes-Palacios MD, Gemma Martín-Ezquerra MD, PhD, Fernando Alfageme MD, PhD, Cristina Ciudad-Blanco MD, PhD, María Teresa López-Villaescusa MD, Patricia Garbayo-Salmons MD, Antonio Martorell MD, PhD, Begoña Escutia-Muñoz MD, PhD, Fernando Navarro-Blanco MD, Daniel Martín-Torregrosa MD, Carlos Cuenca-Barrales MD, PhD, Alejandro Molina-Leyva MD, PhD, Rafael Botella-Estrada MD, PhD
{"title":"比美单抗治疗化脓性扁桃体炎的实际有效性和安全性:一项前瞻性观察研究。","authors":"Miguel Mansilla-Polo MD,&nbsp;Martí Pons-Benavent MD,&nbsp;Pablo Fernández-Crehuet MD, PhD,&nbsp;Eva Vilarrasa MD, PhD,&nbsp;Cristina Albanell-Fernández MD,&nbsp;Enrico Morales-Tedone MD,&nbsp;Francisca Rausell-Félix MD,&nbsp;Rebeca Alcalá-García,&nbsp;María Matellanes-Palacios MD,&nbsp;Gemma Martín-Ezquerra MD, PhD,&nbsp;Fernando Alfageme MD, PhD,&nbsp;Cristina Ciudad-Blanco MD, PhD,&nbsp;María Teresa López-Villaescusa MD,&nbsp;Patricia Garbayo-Salmons MD,&nbsp;Antonio Martorell MD, PhD,&nbsp;Begoña Escutia-Muñoz MD, PhD,&nbsp;Fernando Navarro-Blanco MD,&nbsp;Daniel Martín-Torregrosa MD,&nbsp;Carlos Cuenca-Barrales MD, PhD,&nbsp;Alejandro Molina-Leyva MD, PhD,&nbsp;Rafael Botella-Estrada MD, PhD","doi":"10.1111/ajd.14339","DOIUrl":null,"url":null,"abstract":"<p>In this original research, we present the results in terms of effectiveness and safety of bimekizumab for hidradenitis suppurativa in real clinical practice. Results indicated significant improvement in all activity scores and patient-reported outcomes at week 16, including a notable decrease in mean IHS4 from 27.1 to 15.6 (<i>p</i> &lt; 0.001), HS-PGA from 5.1 to 3.2 (<i>p</i> &lt; 0.001), VAS pain from 8.3 to 4.7 (<i>p</i> &lt; 0.001) and DLQI from 21.6 to 12.6 (<i>p</i> &lt; 0.001). Bimekizumab, administered every 2 or 4 weeks, was well-tolerated with no discontinuations and no new safety concerns identified. These findings corroborate the drug's effectiveness and favourable safety profile observed in phase 3 clinical trials, supporting its use in real-world clinical practice for treating HS.</p>","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":"65 7","pages":"e198-e202"},"PeriodicalIF":2.2000,"publicationDate":"2024-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Real-world effectiveness and safety of bimekizumab for hidradenitis suppurativa: An ambispective observational study\",\"authors\":\"Miguel Mansilla-Polo MD,&nbsp;Martí Pons-Benavent MD,&nbsp;Pablo Fernández-Crehuet MD, PhD,&nbsp;Eva Vilarrasa MD, PhD,&nbsp;Cristina Albanell-Fernández MD,&nbsp;Enrico Morales-Tedone MD,&nbsp;Francisca Rausell-Félix MD,&nbsp;Rebeca Alcalá-García,&nbsp;María Matellanes-Palacios MD,&nbsp;Gemma Martín-Ezquerra MD, PhD,&nbsp;Fernando Alfageme MD, PhD,&nbsp;Cristina Ciudad-Blanco MD, PhD,&nbsp;María Teresa López-Villaescusa MD,&nbsp;Patricia Garbayo-Salmons MD,&nbsp;Antonio Martorell MD, PhD,&nbsp;Begoña Escutia-Muñoz MD, PhD,&nbsp;Fernando Navarro-Blanco MD,&nbsp;Daniel Martín-Torregrosa MD,&nbsp;Carlos Cuenca-Barrales MD, PhD,&nbsp;Alejandro Molina-Leyva MD, PhD,&nbsp;Rafael Botella-Estrada MD, PhD\",\"doi\":\"10.1111/ajd.14339\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>In this original research, we present the results in terms of effectiveness and safety of bimekizumab for hidradenitis suppurativa in real clinical practice. Results indicated significant improvement in all activity scores and patient-reported outcomes at week 16, including a notable decrease in mean IHS4 from 27.1 to 15.6 (<i>p</i> &lt; 0.001), HS-PGA from 5.1 to 3.2 (<i>p</i> &lt; 0.001), VAS pain from 8.3 to 4.7 (<i>p</i> &lt; 0.001) and DLQI from 21.6 to 12.6 (<i>p</i> &lt; 0.001). Bimekizumab, administered every 2 or 4 weeks, was well-tolerated with no discontinuations and no new safety concerns identified. These findings corroborate the drug's effectiveness and favourable safety profile observed in phase 3 clinical trials, supporting its use in real-world clinical practice for treating HS.</p>\",\"PeriodicalId\":8638,\"journal\":{\"name\":\"Australasian Journal of Dermatology\",\"volume\":\"65 7\",\"pages\":\"e198-e202\"},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2024-06-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Australasian Journal of Dermatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/ajd.14339\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Australasian Journal of Dermatology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/ajd.14339","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

在这项原创研究中,我们介绍了比美单抗在实际临床实践中治疗化脓性扁桃体炎的有效性和安全性。结果表明,在第 16 周时,所有活动评分和患者报告结果均有明显改善,包括 IHS4 平均值从 27.1 显著降至 15.6(p
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Real-world effectiveness and safety of bimekizumab for hidradenitis suppurativa: An ambispective observational study

In this original research, we present the results in terms of effectiveness and safety of bimekizumab for hidradenitis suppurativa in real clinical practice. Results indicated significant improvement in all activity scores and patient-reported outcomes at week 16, including a notable decrease in mean IHS4 from 27.1 to 15.6 (p < 0.001), HS-PGA from 5.1 to 3.2 (p < 0.001), VAS pain from 8.3 to 4.7 (p < 0.001) and DLQI from 21.6 to 12.6 (p < 0.001). Bimekizumab, administered every 2 or 4 weeks, was well-tolerated with no discontinuations and no new safety concerns identified. These findings corroborate the drug's effectiveness and favourable safety profile observed in phase 3 clinical trials, supporting its use in real-world clinical practice for treating HS.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
3.20
自引率
5.00%
发文量
186
审稿时长
6-12 weeks
期刊介绍: Australasian Journal of Dermatology is the official journal of the Australasian College of Dermatologists and the New Zealand Dermatological Society, publishing peer-reviewed, original research articles, reviews and case reports dealing with all aspects of clinical practice and research in dermatology. Clinical presentations, medical and physical therapies and investigations, including dermatopathology and mycology, are covered. Short articles may be published under the headings ‘Signs, Syndromes and Diagnoses’, ‘Dermatopathology Presentation’, ‘Vignettes in Contact Dermatology’, ‘Surgery Corner’ or ‘Letters to the Editor’.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信